Table 3.
Age at Tumor Diagnosis and PPCM, Baseline LVEF at PPCM Diagnosis, LVEF After Anticancer Treatment, and Genetic Variants in PPCM Patients With Cancer After PPCM
| Patient # | Tumor Diagnosis | Age at Tumor Diagnosis (yrs) | Age at PPCM | Baseline LVEF | LVEF After Cancer Therapy | Anticancer Therapy | Genetic Variant (P/LP/VUS) |
|---|---|---|---|---|---|---|---|
| 09 | Breast cancer | 48 | 36 | 40 | 46 | Antihormone therapy, surgery, radiation |
TTN (P) ATM (P) ERCC5 (P) |
| 13 | Breast cancer | 44 | 40 | 24 | 52 | Chemotherapy (paclitaxel), antihormone therapy, surgery, radiation | TTN (VUS) POLD1 (VUS) |
| 14 | Breast cancer | 37 | 36 | 20 | 59 | Chemotherapy (paclitaxel, carboplatin), surgery |
TTN (LP) NBN (P) |
| 15 | Colorectal cancer | 33 | 31 | 30 | 60 | Surgery | Not performed |
| 16 | Prolactinoma | 30 | 30 | 12 | HTX | No antitumor therapy | Not performed |
| 17 | Ovarian cancer | 36 | 31 | 29 | 55 | Surgery | RYR1 (VUS) |
| 18 | Microprolactinoma | 31 | 31 | 30 | 58 | No antitumor therapy but bromocriptine | Not performed |
| 19 | Cervical cancer | 45 | 39 | 30 | 50 | Surgery | Not performed |
| 20 | Breast cancer | 51 | 39 | 22 | 50 | Chemotherapy: tamoxifen; radiation; surgery | Not performed |
| 21 | Cervical cancer | 41 | 40 | 32 | 55 | Surgery | Not performed |
Cardiac function at the time of diagnosis and after cancer therapy in PPCM patients with malignancies after PPCM. PPCM patient 9 had Hodgkin lymphoma before PPCM and breast cancer after PPCM (see Table 2). Variants identified by exome sequencing are presented with their corresponding American College of Medical Genetics and Genomics class. All LP/P variants are in bold.
ATM = TM serine/threonine kinase; ERCC5 = excision repair cross-complementation group 5; HTX = heart transplantation; LP = likely pathogenic; LVEF = left ventricular ejection fraction; NBN = nibrin; P = pathogenic; POLD1 = polymerase delta 1; PPCM = peripartum cardiomyopathy; RYR1 = ryanodine receptor 1; TTN = titin; VUS = variant of unknown significance.